Anthos Therapeutics Inc.

Six years after licensing out abelacimab to Anthos Therapeutics, a venture it co-founded with Blackstone Life Sciences, Novartis has brought the drug back into its cardiovascular pipeline. The Swiss g

Regeneron Pharmaceuticals expects to see downward pressure on the 2mg version of Eylea (aflibercept) continue after 2024, but demand for the VEGF inhibitor has remained high despite the introduction o

In a battle with Bristol Myers Squibb/Johnson & Johnson, Bayer and privately held Anthos to bring the first factor XI anticoagulant product to market, Regeneron reported on 19 December that its pa

The first days of the new year witnessed multinationals including Novartis AG tie up with developers of small interfering RNA therapies from China, once regarded as a backwater for R&D into such a n